Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations

Journal of Molecular Biology(2021)10.1016/j.jmb.2021.167177Source: DataRank Database

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations is a research paper published in Journal of Molecular Biology (2021). On theSindex it has a DataRank of 0. It has been cited 43 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access43 citations

Download PDF

Cite:

Linked data & code

emdb nct pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 2.35)OA: greenTopics (97)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (28)

Zhijie Li ORCID,Reza Saberianfar,Mart Ustav ORCID,James Brett Case ORCID,Levi L. Blazer ORCID

Live enrichment

PubMed:34329642 PMC:PMC8316672 OpenAlex:https://openalex.org/W3185257208

Foundation for Angelman Syndrome Therapeutics

Grant: 2161

Foundation for Angelman Syndrome Therapeutics

Grant: 2189

Canadian Institutes of Health Research

Grant: 3-170649

National Institutes of Health

Grant: R01 AI157155

Defense Advanced Research Projects Agency

Grant: HR001117S0019

Defense Advanced Research Projects Agency

Grant: P01AI120943

Defense Advanced Research Projects Agency

Grant: R01AI107056

Defense Advanced Research Projects Agency

Grant: R01AI123926

Canadian Institutes of Health Research

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5R01AI157155-02

Human antibody-based countermeasures against the Coronavirus SARS-CoV-2

National Institutes of Health

Grant: 4R01AI107056-04

STRUCTURAL BASIS FOR IMMUNE EVASION BY RSV NON-STRUCTURAL PROTEINS

National Institutes of Health

Grant: 5P01AI120943-03

Structural and Functional Characterization of the Ebola Virus Replication Complex

National Institutes of Health

Grant: 5R01AI123926-02

Multi-platform High Throughput Screens for Filoviral Replication Inhibitors

Fondazione Roma

Regione Lazio

Meso Scale Diagnostics

FWCI

2.35

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8316672

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781305

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8316672

publisherhttps://api.elsevier.com/content/article/PII:S0022283621004101?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022283621004101?httpAccept=text/plain

Fields of Study

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchViral Infections and Immunology ResearchMedicine0301 basic medicine03 medical and health sciences0303 health sciencesAngiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsBinding SitesCOVID-19Chlorocebus aethiopsHEK293 CellsHumansImmunoglobulin GModels, MolecularMutationProtein BindingProtein EngineeringSARS-CoV-2Spike Glycoprotein, CoronavirusVero CellsCOVID-19 Drug Treatment

MeSH Terms

Angiotensin-Converting Enzyme 2COVID-19SARS-CoV-2COVID-19 Drug TreatmentAnimalsAntibodies, ViralAntiviral AgentsBinding SitesChlorocebus aethiopsHumansImmunoglobulin GModels, MolecularMutationProtein BindingVero CellsProtein EngineeringAntibodies, NeutralizingHEK293 CellsSpike Glycoprotein, Coronavirus

Keywords

AvidityBivalent (engine)PotencyVirologyAntibodyNeutralizing antibodyChemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MutantCoronavirus disease 2019 (COVID-19)BiologyVirusIn vitroBiochemistryImmunologyMedicineInfectious disease (medical specialty)GeneSyntheticAnti-viralNeutralizingTetravalentRbd-BindingModels, Molecular570Settore MED/03 - GENETICA MEDICAAntibodies, ViralProtein EngineeringAntiviral AgentsAntibodiesModelsChlorocebus aethiopsAnimalsHumansViralsars-cov-2; antivirals; monoclonal antibodiesVero CellsBinding SitesSARS-CoV-2MolecularCOVID-19Antibodies, NeutralizingSpike GlycoproteinCOVID-19 Drug TreatmentCoronavirusHEK293 CellsImmunoglobulin GMutationSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Research ArticleProtein Binding

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Cell-based passive immunization for protection against SARS-CoV-2 infection

10.6084/m9.figshare.26636607.v1figshare

Additional file 1 of Cell-based passive immunization for protection against SARS-CoV-2 infection

10.6084/m9.figshare.26636607figshare

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations

FAIR Checklist

Authors (28)

Funding (16 grants)

Impact

Open Access

Topics

Linked Datasets (2)

Annotations (Europe PMC)